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Breast cancer cells modulate lipid and fatty acid metabolism to sustain proliferation.
The role of adipocytes in cancer treatment efficacy remains, however, to be fully
elucidated. We investigated whether diet-induced obesity (DIO) affects the efficacy of
doxorubicin treatment in a breast tumor-bearing mouse model. Female C57BL6 mice
were fed a high fat or low fat diet for the full duration of the study (12 weeks). After
8 weeks, mice were inoculated with E0771 triple-negative breast cancer cells in the
fourth mammary gland to develop breast tumor allographs. Tumor-bearing mice received
either vehicle (Hank’s balanced salt solution) or doxorubicin (chemotherapy). Plasma
inflammatory markers, tumor, and mammary adipose tissue fatty acid composition, as
well as protein expression of lipid metabolism markers were determined. The high fat
diet (HFD) attenuated the treatment efficacy of doxorubicin. Both leptin and resistin
concentrations were significantly increased in the HFD group treated with doxorubicin.
Suppressed lipogenesis (decreased stearoyl CoA-desaturase-1) and lipolysis (decreased
hormone-sensitive lipase) were observed in mammary adipose tissue of the DIO animals,
whereas increased expression was observed in the tumor tissue of doxorubicin treated
HFD mice. Obesogenic conditions induced altered tissue fatty acid (FA) compositions,
which reduced doxorubicin’s treatment efficacy. In mammary adipose tissue breast
cancer cells suppressed the storage of FAs, thereby increasing the availability of free
FAs and favored inflammation under obesogenic conditions.
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INTRODUCTION
The incidence of lifestyle associated conditions including obesity is a rising epidemic (1), this
is especially alarming since breast cancer remains a major health risk for women globally (2).
Obesity is identified as a casual factor in both the development as well as the progression of breast
carcinogenesis (3, 4), and is characterized by rapid adipose tissue remodeling (hypertrophy and
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hyperplasia) (5), increased synthesis of several adipokines such as
leptin, resistin, tumor necrosis factor-alpha (TNF-α), interleukin
(IL)-1β, IL-6, macrophage chemoattractant protein-1 (MCP-
1), and immune cell infiltration, all of which lead to a state
of sustained low-grade inflammation. Mammary adipose tissue
serves as a exogenous source of energy metabolites which
favors the proliferation demand of breast cells in the tumor
microenvironment (6, 7). On the other hand, breast cancer cells
can also modulate lipid metabolism by altering both de novo
fatty acid (FA) synthesis as well as the catabolic break down
of triacylglycerol’s (TAGs) a process known as lipolysis. This
subsequently results in the release of free fatty acids (FFAs) which
become available metabolic substrates for the benefit of breast
cancer cell survival, either by storage in the form of lipid droplets,
membrane lipids or energy production via β-oxidation supplying
energy to these proliferating breast cancer cells (6, 8).
The role of FAs in cancer progression and treatment resistance
implicates various physiological functions of FAs in relation to
both dietary intake and de novo synthesized FAs. It is proposed
to be achieved by (i) alterations in cell membrane composition,
(ii) the biosynthesis of lipid-signaling molecules, and (iii) its role
in metabolic reprogramming as an energy source [reviewed in
(9, 10)]. Both SFAs and MUFAs are implicated in alterations
within cancer cell membrane composition known as membrane
lipid saturation. These FA classes are more resistant to lipid
peroxidation, which in turn protects cancerous cells against
oxidative stress induced by therapies (11, 12). The role of omega-
6 (n-6) PUFAs in breast cancer development, progression as
well as treatment resistance, includes n-6 PUFAs exhibiting
pro-inflammatory effects mediated by lipid-derived bioactive
mediators i.e., eicosanoids, prostaglandins and leukotrienes
(13, 14). These lipid-derived bioactive mediators upregulate
signaling pathways that are involved in inflammation, which
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exacerbate angiogenesis, cell-proliferation and inflammation
(15), to contribute to an ideal microenvironment favoring
mammary carcinogenesis.
Recently, findings from cell culture and animal models
identified obesity as a main contributing factor in the underlying
pathophysiology implicated in the development of breast cancer
chemotherapeutic drug resistance (16, 17). Patients suffering
from obesity and breast cancer presented with poor clinical
outcomes when treated with first line adjuvant regimens such
as doxorubicin (18, 19). Despite doxorubicin’s high efficacy
in killing cancer cells, its’ clinical efficacy is hindered by the
development of various cellular toxicities which contributes
to the development of chemotherapeutic drug resistance (20).
Doxorubicin treatment is also associated with cellular toxicities
in adipose tissue (primary storage site for FAs) which in turn
leads to dysfunctional lipid/FA storage (21, 22). Therefore,
FA tissue composition may also be significantly altered by
chemotherapeutic agents.
A lack of evidence highlighting the role of FAs in breast
cancer treatment efficacy, as well as an incomplete understanding
of cellular mechanisms whereby obesity affects chemotherapy
outcomes, necessitates further investigation. We therefore aimed
to determine whether diet-induced obesity (DIO) affects the
efficacy of doxorubicin treatment in a breast tumor-bearing
mouse model and to explore possible mechanisms of action.
METHODS
Female C57BL6 mice were fed a low fat diet (LFD) or a
high fat diet (HFD) for 12 weeks. After developing the DIO
phenotype, syngeneic breast tumors were induced, followed by
respective treatments.
Animals and Handling
Animal handling and interventions were carried out under
the supervision of a registered small animal handling expert
at the Stellenbosch University. Ethical clearance was obtained
from Stellenbosch University animal research committee
(SU-ACUM13-00015). All protocols strictly adhered to the
standard care guidelines of laboratory animals implemented
at Stellenbosch University and according to the South African
National Standards 10386:2008 for the use of animals in research
and teaching.
Three-week-old female C57BL6 mice (n = 40) were
maintained in the animal research facility at the University of
Stellenbosch in static micro-isolation sterilized cages (n = 5 per
cage) with filtered air. The mice were provided with chow and
water ad libitum in a regular 12:12 h light-dark cycle. All animals
were acclimated for 1 week followed by the assignment to either
HFD or LFD groups. The general welfare of all animals were
monitored daily.
Diet Regimens
A HFD was used to induce obesity since reported evidence
showed that genetic models of obesity (i.e., ob/ob, db/db, and
leptin/ leptin receptor-deficient mice) demonstrated resistance in
developing mammary cancer (23). C57BL6 mice are particularly
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FIGURE 1 | Representative summary of the in vivo model and respective experimental groups.
sensitive to DIO (24). Forty mice (n = 40) were randomly
assigned into two equal groups (n= 20) and allocated one of two
respective diets for 12 weeks (Figure 1). The energy content of the
HFD (D12492, Research diet Inc., New Jersey, USA) consisted of
60% energy from fat, 20% energy from protein, and 20% energy
from carbohydrates, compared to the LFD (D12450J, Research
diet Inc., New Jersey, USA), containing 10% energy from fat,
20% energy from protein, and 70% energy from carbohydrates
(Table 1). The dietary FA composition of the respective diets
is summarized in Supplementary Table 1. Body weight was
monitored weekly over the study period and the DIO phenotype
was confirmed after 8 weeks followed by tumor induction.
Tumor Induction
Cell Culture
An aggressive triple-negative breast cancer cell line with
metastatic capabilities (E0771) that originated from a tumor
after a spontaneous mutation in a C57BL6 mouse, was used
in this in vivo model. The cells were cultured in T75 flasks
(75 cm2, SPL Life Sciences, Pocheon-si, South Korea) with
Dulbecco’s Modified Eagle’s medium (DMEM, Gibco R©,
ThermoFisher Scientific, Massachusetts, United States)
under standard incubation conditions (37◦C and 5% CO2
humidity), supplemented with 10% fetal bovine serum (FBS,
Capricorn Scientific, Germany) and 1% Penicillin Streptomycin
(PenStrep Gibco, ThermoFisher Scientific, Massachusetts,
United States). Growth media was replaced every 2 day.
Regular sub-culturing was performed once cultures reached
70–80% confluency.
Inoculation of Tumors
E0771 cells were prepared for each mouse. The mice were
anesthetized under 3% (v/v) isoflurane (Isofor, Safeline
Pharmaceuticals, Johannesburg, South Africa) in an anesthetic
chamber. Mice were inoculated subcutaneously (using a 23-
gauge needle syringe) in the fourth left mammary fat pad with
1.2 × 105 E0771 triple-negative breast cancer cells suspended
in Hanks Balanced Salt Solution (HBSS) (Sigma Chemical Co.,
St Louis, MO, USA) as illustrated in Figure 1.
Drug Administration
Once tumors became palpable (200–300mm2), LFD and HFD
mice were randomly assigned to the respective treatment groups
(Figure 1). The treatment groups included: (1) vehicle control
(isovolumetric intra-peritoneal injection of HBSS), and (2)
doxorubicin treatment (D5794, LKT R© laboratories, Minnesota,
USA). Mice were restrained and treated with three dosages
of 4 mg/kg doxorubicin (cumulative dosage of 12 mg/kg) via
intraperitoneal injection. The dosage of 12 mg/kg doxorubicin
is equivalent to 36 mg/m2 in humans which is within the
clinically relevant dosage range of doxorubicin treatment (15–
90mg/m2) (25).
The experimental groups were assigned as follows: (i) tumor
vehicle-LFD (vehicle-L), (ii) tumor vehicle-HFD (vehicle-H), (iii)
tumor doxorubicin-LFD (Dox-L), and (iv) tumor doxorubicin-
HFD (Dox-H). Humane endpoints were implemented when
tumor growth influenced the general welfare or restricted
mobility of the mice, or when the mice began to bite their
tumors and exhibit changes in posture and facial expression,
as determined by the grimace scale. The final sample size per
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TABLE 1 | Dietary composition of low fat diet and high fat diet.
Low Fat Diet (LFD) High Fat Diet (HFD)
Research diet D12450J Research diet D12492
gram% kcal% gram% kcal%
Protein 19.2 20 26.2 20
Carbohydrates 67.3 70 26.3 20
Fat 4.3 10 34.9 60
Total 100 100
Kcal/gm 3.85 5.24
INGREDIENTS gram kcal gram kcal
Casein, 30 Mesh 200 200 800 200 800
L-Cystine 3 12 3 12
Corn starch 506.2 2024.8 0 0
Maltodextrin 10 125 500 125 500
Sucrose 68.8 275.2 68.8 275.2
Cellulose BW200 50 0 50 0
Soybean oil 25 225 25 225
Lard 20 180 245 2,205
Mineral mix S10026 10 0 10 0
Dicalcium phosphate 13 0 13 0
Calcium carbonate 5.5 0 5.5 0
Potassium citrate, 1 H2O 6.5 0 6.5 0
Vitamin mix V10001 10 40 10 40
Choline bitartrate 2 0 2 0
FD&C yellow dye #5 0.04 0
FD&C blue dye #1 0.01 0 0.05 0
TOTAL 1055.1 4,057 773.9 4057.0
Cholesterol (mg)/4057 kcal – 54.4 – 216.4
Cholesterol (mg)/kg – 51.6 – 279.6
As per manufacturer product data sheet (Research diet Inc., New Jersey, USA).
experimental group were as follows: vehicle-L (n = 8), vehicle-H
(n= 9), Dox-L (n= 10), and Dox-H (n= 9).
Measurements, Blood Collection, and Tumor- and Fat
Tissue Excision
Every second day, animals were weighed and tumor location and
volume were recorded. The absolute body weight was calculated
after subtracting tumor weight. Tumor growth was measured
using a Harpenden caliper (in mm) to determine tumor volume
using the following equation:
Tumour Volume
(
mm3
)
=
1
2
(
length×width2
) (26)
Animals were euthanised 72 h after the last scheduled
doxorubicin administration. Mice were anesthetized under
3% isoflurane and sacrificed by cervical dislocation after a deep
sleep was confirmed by the absence of pedal reflex. Whole blood
was immediately collected into pediatric EDTA tubes (Lasec,
Cape Town, South Africa) from the thoracic cavity. Collected
blood samples were placed on ice and centrifuged (1,000 RCF
(g), 10min), to collect and aliquot plasma which was stored at
−80◦C for subsequent analysis. Mammary adipose tissue was
collected from the third and fourth quadrant of the mice and
tumor tissue were dissected, weighed, snap-frozen with liquid
nitrogen and stored at −80◦C or stored in formalin at room
temperature for immunohistochemistry analysis.
Blood Analysis
Plasma samples were used to quantify TNF-α, IL-6, IL-10, leptin
(PPX-04-MXCE327, Thermo Fisher Scientific, United States),
IL-1β and vascular endothelial growth factor (VEGF-A) (PPX-
02-MXFVKXT, Thermo Fisher Scientific, United States) using a
custom ProcartaPlex panel and matched mouse Luminex kits. A
Milliplex mouse adipokine magnetic bead panel MAP kit was
used to quantify MCP-1, insulin, total plasminogen activator
inhibitor-1 (PAI-1) and resistin (MADKMAG-71K, Burlington,
Massachusetts, United States). All analyses were performed
according to the manufacturers’ protocols and specifications.
Analytes were measured simultaneously using aMAGPIX system
plate reader (APX1042, Bio-Rad, California, United States) and
data (expressed in pg/ml) was processed on Bioplex Software 6.1
(Bio-Rad, California, United States).
Determination of Tissue Fatty Acid Profiles
For tumor tissue, FA composition of the total phospholipid
(TPL) and the FFA fractions were determined, whereas for
the mammary adipose tissue, the total lipid FA composition
was determined. Frozen tumor tissue and mammary adipose
tissue were allowed to thaw at room temperature. Approximately
100mg of tumor tissue and 30mg of adipose tissue were weighed
for lipid extraction using chloroform:methanol (C:M; 2:1; v:v;
Sigma-Aldrich, St. Louis, Missouri, United States) according to
a method adapted from Folch et al. (27) as previously described
by Hon et al. (28). The extraction solvent contained 0.01%
butylated hydroxytoluene (Sigma-Aldrich, St. Louis, Missouri,
United States), acting as an antioxidant.
Briefly, lipids of tumor tissue were extracted with 9mL of C:M
(2:1; v:v) by homogenisation for 1min using a Polytron R© PT-
MR 3100D homogeniser (Kinematica, Luzern, Switzerland). The
homogenate was filtered through a sintered glass funnel with
the filter pad lined with a glass microfiber filter disk (GF/A,
Whatman, England) into a round bottom flask. The Polytron R©
shaft was rinsed with another 7mL of the extracting solvent
and filtered, collecting the rinse into a round bottom flask.
The microfiber filter disk containing the homogenized tissue
was removed and placed into an extraction tube and extracted
again with 10mL C:M (2:1; v:v) by 20-min shaking and a
filtering step (repeated twice). The combined extraction phases
containing the lipids were concentrated to dryness through
rotary evaporation in a 37◦C water bath (BÜCHI Labortechnik,
Postfach, Switzerland). Lipids were transferred from the round
bottom flask to a 12mL glass tube with screw cap using 5 ×
2mL chloroform:methanol:saline (CMS; 86:14:1; v:v:v; Sigma-
Aldrich) transfer volumes. Saline saturated with CMS (1mL)
was added, mixed and centrifuged, and the top saline layer was
completely removed in order to concentrate the bottom phase to
dryness under nitrogen gas flow in a 37◦C water bath.
Neutral lipids were separated from the TPL fraction using
thin-layer chromatography (TLC) silica gel 60 plates (10× 10 cm;
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No. 1.05626.0001; Merck, Darmstadt, Germany) and eluted with
the solvent system petroleum ether (B&M Scientific, Cape Town,
South Africa):diethyl ether (Merck):acetic acid (Merck) (90:30:1;
v:v:v). The lipid bands containing the TPL and FFA fractions
were demarcated by visualization under long-wave UV light after
plates were sprayed with C:M (1:1; v:v) containing 2,5-bis-(5
′
-
tert-butylbenzoxazolyl-[2′]) thiophene (10mg/100mL; Sigma-
Aldrich). These lipid bands were scraped off the plates into
glass tubes with screw caps. The lipids were trans-esterified
through trans-methylation with 2mL methanol:sulphuric acid
(H2SO4; BDH Chemicals, Poole, England) (95:5; v:v) at 70◦C
for 2 h to yield FA methyl esters (FAMEs). After cooling, the
FAMEs were extracted with distilled water (1mL) and n-hexane
(3mL) (Sigma-Aldrich). The upper hexane layer containing the
FAMEs was collected and evaporated to dryness for subsequent
gas-liquid chromatography (GLC) analysis.
Total lipids were extracted frommammary adipose tissue with
9mL C:M (2:1; v:v) by shaking for 20min with a mechanical
shaker. Subsequently, 1.8mL saline saturated with CMS was
added, mixed and centrifuged at 60 RCF (g) for 10min at 4◦C.
The bottom phase was collected and transferred to a 12mL glass
tube with a screw cap and the lipid extract evaporated to dryness
under nitrogen gas flow using a 37◦C water bath. The dried lipids
were re-dissolved in 3mL C:M (2:1; v:v) of which a 50 µL aliquot
was transferred to a clean 12mL glass tube and the lipid aliquot
was evaporated to dryness as described before. These lipids were
trans-methylated with 2mL methanol:sulphuric acid (70◦C for
2 h) with subsequent sample FAME isolation for GLC analysis as
described above.
All FAMEs were re-dissolved in n-hexane and analyzed
(sample injection volume 1 µl) by GLC on a Finnigan Focus
Gas Chromatograph (Thermo Electron Corporation, Austin, TX,
USA) equipped with a flame-ionization detector and a 30m
capillary column of 0.32mm internal diameter (BPX70 0.25µm;
SGE International, Ringwood, Victoria, Australia). Gas flow
rates were: N2 (make up gas), 25 mL/min; synthetic air, 250
mL/min; and H2 (carrier gas), 25 mL/min, with a 20:1 split ratio.
Oven temperature programming was linear at 4.5◦C/min, initial
temperature 140◦C (hold-time 1min), final temperature 220◦C
(hold-time 5min), injector temperature 220◦C, and detector
temperature 250◦C [as previously described (29)].
All sample FAMEs were subsequently identified by analyzing
and comparing sample retention times with those a known
standard FAME mixture (27 FAMEs, NuChek Prep, Elysian,
MN, USA). Relative percentages of each individual FAME was
calculated by determining the area count of a specific FAME as a
percentage of the total area count of all FAMEs identified in the
sample. Estimated desaturase indexes were estimated by product
to precursor FA ratios which included stearoyl CoA-desaturase-
1 (SCD1)-16 calculated as the ratio of palmitoleic acid (PTA) to
palmitic acid (PA) and SCD1-18 calculated as the ratio of oleic
acid (OA) to stearic acid (SA) (30, 31).
Protein Analysis and Western Blot Analysis
Mammary adipose tissue and tumor tissue samples were
placed on ice and allowed to thaw at 4◦C. Total protein
extraction was performed where samples were suspended in
300µl of cold modified radio-immunoprecipitation (RIPA) assay
buffer containing protease and phosphatase inhibitors (2.5mM
Tris-HCL, 0.1mM phenylmethylsulfonyl fluoride, 10 mg/ml
leupeptin, 1mM EDTA, 1mM benzamidine, 50mM sodium
fluoride, 1mM dithiothreitol, 4 mg/ml soybean trypsin inhibitor,
0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate,
and 1% NP-40, pH 7.4). Samples were homogenized on ice
under sterile conditions to prevent protein cross-contamination.
Next, all samples were centrifuged (35,000 RCF (g), 60min,
4◦C), to yield distinct layers. The supernatant layer was
removed using a sterile 23-gauge needle and syringe and
transferred into sterile Eppendorf tubes, followed by another
centrifugation step (35,000 RCF (g), 30min, 4◦C). The process
of removing the supernatant was repeated and samples were
run through Amicon R© Ultra 0.5mL filters (Merck, Darmstadt,
Germany) for protein purification and concentration and
stored at −80◦C, until protein quantification using a Direct
Detect R© infrared spectrometer (DDHW00010-WW, Merck).
This was followed by preparation of protein aliquots containing
20–50 µg protein diluted with Laemmli sample buffer and
boiled for 5min (to denature proteins) before being loaded
into 4–15% polyacrylamide fast cast gels (mini-PROTEAN R©
TGXTM Gels, Bio-Rad) for separation by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). Gels were run at
100V (constant) and 400mA for approximately 60min (Power
Pac 300, BioRad). The electro-transfer of proteins from the gel
to prepared polyvinylidene fluoride (PVDF) membranes was
achieved using a semi-dry electro-transfer system (TransBlot R©
TurboTM v1.02, BioRad) for 30min at 25V and 1.0A. Transfer
efficiency was evaluated using the stain-free blot protocol
provided on a Chemi-DocTM MP (BioRad) system. Subsequently,
all membranes were washed with 0.1% Tris Buffered Saline-
Tween 20 (TBS-T) and blocked for 60min in 5% (w/v) non-
fat milk and TBS-T at room temperature to prevent non-
specific binding. The PVDF membranes were then incubated
overnight in primary antibody solutions (1:1,000, diluted in
5% w/v BSA, 1X TBS-T, refer to Supplementary Table 2) at
4◦C. The following day, membranes were washed three times
for 5min each with TBS-T, prior to incubation with an
anti-rabbit IgG horseradish peroxidase conjugated secondary
antibody (1:10,000) (Cell Signaling Technologies, Massachusetts,
United States), for 60 min at room temperature. A wash
step followed, using TBS-T (five times for 5min each), before
specific bands were visualized and detected using the enhanced
chemiluminescence (ECL) western blotting substrate detection
kit (Pierce R©, Thermo Scientific) and ImageLab 4.0 software
on a Chemi-DocTM MP (BioRad) imaging system. Protein
quantification of samples were normalized to total protein
signal in each lane present on the same membrane after
blotting (ImageLab 4.0 software, Biorad USA), as determined
by the Stain-FreeTM (ImageLab 4.0 software, Biorad USA)
properties of the blot and is expressed as a percentage of
the control.
Haematoxylin and Eosin Stained Tumor
Tissue
Sectioning, deparaffinization and rehydration of tumor
tissue samples was performed as previously described
(32). Tumor tissue samples were stained for histological
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changes using haemotoxylin and eosin (H&E) staining.
Staining was achieved by using an automated tissue
stainer (Leica Biosystems, ST4020), during which section
slides where dipped into haemotoxylin. This was followed
by various subsequent 2-min dipping steps in distilled
water, scott’s tap water, distilled water, eosin and distilled
water followed by coverslips being mounted using DPX
mounting media.
Statistical Analysis
Statistical analyses were performed using Statistica version 13.3
(TIBCO Software, California, United States). Normality was
assessed using the Shapiro-Wilk test and results were reported
as mean ± standard error of the mean (SEM). To describe
differences between two groups, t-tests were used, and to
describe differences between the three/more groups two- or
three-way ANOVA were used, followed by the Fisher’s LSD
post-hoc test. Pearson’s correlations were used on selected
parameters in each group and 2D scatter plots were drawn
up in GraphPad Prism version 7 (GraphPad Software, San
Diego, United States). Statistical significance was accepted
at p< 0.05.
RESULTS
A High Fat Diet Increased Body Weight and
Mammary Adipose Tissue Weight
Body Weight and Food Consumption
During the DIO period, mice that were fed the HFD showed
significantly higher body weights at week 6 (p < 0.01), week 7
(p< 0.001) and week 8 (p< 0.0001), compared to the LFD group
(Figure 2A), therefore DIO was established after 8 weeks. It was
also observed that mice fed a HFD showed significantly lower
food consumption per cage at week 2 (p < 0.001), 3 (p < 0.01)
and 4 (p< 0.05) compared to the LFD group (Figure 2B).
Following tumor induction, mice in the vehicle-H group
showed significantly higher body weight compared to vehicle-L
mice during week 8–12 (all p< 0.001) (Figure 3A). A similar and
statistically significant observation was made for body weight of
mice in the Dox-H group, when compared to Dox-Lmice at week
8–12 (all p < 0.01) (Figure 3A). The Dox-H mice also showed
significantly lower food consumption compared to the vehicle-H
mice at week 8 (p < 0.0001), 9 (p < 0.0001), 10 (p < 0.001), 11
(p < 0.001), and 12 (p < 0.0001) (Figure 3B). Lastly, the Dox-
H mice revealed significantly lower food consumption than the
FIGURE 2 | Difference in (A) body weight and (B) food consumption in mice (n = 5 per cage) on the LFD and HFD for 8 weeks. Results are presented as mean ±
SEM (n = 20 per group). T-tests were used for comparison between the LFD and the HFD mice for all weeks and p < 0.05 was considered as statistically significant.
*p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
FIGURE 3 | (A) Mean body weight, and (B) food consumption of mice (n = 5 per cage) receiving vehicle-or doxorubicin treatment while on the LFD control compared
to the HFD. Results are presented as mean ± SEM (n = 10 per group). Three-way ANOVA with Fisher’s LSD post hoc correction was applied and p < 0.05 was
considered as statistically significant. ***p < 0.001 and ****p < 0.0001. #p < 0.05, ##p < 0.01, ####p < 0.0001, $$$p < 0.001 and $$$$p < 0.0001. *Vehicle-L
vs. Vehicle-H, #Dox-L vs. Dox-H, and $Vehicle-H vs. Dox-H.
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Dox-L mice at week 8 (p < 0.05), 9 (p < 0.01), 10 (p < 0.05), 11
(p< 0.01), and 12 (p< 0.0001) (Figure 3B).
Mammary Adipose- and Tumor Tissue
Weight
The vehicle-H mice showed significantly higher mammary
adipose tissue weight (p < 0.01) and tumor weight (p < 0.05)
in comparison to the vehicle-L mice (Figures 4A,B). Mice in
the Dox-H group presented with significantly higher mammary
adipose tissue weight (p < 0.05) as well as tumor weight (p <
0.01) compared to Dox-L mice (Figures 4A,B).
Diet-Induced Obesity Decreased
Doxorubicin Treatment Efficacy in Breast
Tumors
Mice in the vehicle-H group showed significantly higher tumor
volume compared to corresponding vehicle-L mice at day 18 (p
< 0.05), 19 (p< 0.05), 20 (p< 0.01), 21 (p< 0.001), 22 (p< 0.01),
23 (p < 0.01), 24 (p < 0.05), 25 (p < 0.01), 26 (p < 0.0001), and
27 (p< 0.0001), as illustrated in Figure 5.
Similarly, mice in the Dox-H group showed significantly
higher tumor volume compared to corresponding mice from the
Dox-L group, at day 21 (p < 0.05), 23 (p < 0.05), 24 (p < 0.001),
25 (p < 0.01), 26 (p < 0.0001), and 27 (p < 0.0001) (Figure 5).
Dox-L mice also had significantly lower tumor volumes at day 27
compared to vehicle-L mice (p < 0.01), and Dox-H mice yielded
significantly lower tumor volume at day 26 (p < 0.05) and 27 (p
< 0.01) compared to the vehicle-H mice (Figure 5).
Diet-Induced Obesity Induced Systemic
Inflammation and Local Inflammatory
Signaling in Mammary Adipose Tissue of
Obese Mice Treated With Doxorubicin
A trend toward significance was observed for IL-6 in Dox-H
mice compared to vehicle-H mice (p= 0.067, Figure 6A). Leptin
FIGURE 4 | Differences in (A) mammary adipose tissue weight, and (B) tumor weight of vehicle- and doxorubicin-treated groups on LFD control compared to HFD.
Results are presented as mean ± SEM (n = 9–10 per group). Two-way ANOVA with Fisher’s LSD post hoc correction were applied. *p < 0.05, **p < 0.01.
FIGURE 5 | Differences in tumor volume for the vehicle control and doxorubicin treatment groups on LFD and HFD. Results are presented as mean ± SEM (n = 10
per group). Three-way ANOVA with Fisher’s LSD post hoc correction was applied and p < 0.05 was considered as statistically significant. *p < 0.05, **p < 0.01,
***p < 0.001, and ****p < 0.0001. #p < 0.05, ##p < 0.01, ###p < 0.001, and ####p < 0.0001, $p < 0.05. *Vehicle-L vs. Vehicle-H, #Dox-L vs. Dox-H,
@Vehicle-L vs. Dox-L, $Vehicle-H vs. Dox-H. @@p < 0.01, $$p < 0.01.
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FIGURE 6 | Mean inflammatory marker concentrations for vehicle control and doxorubicin treatment groups on LFD and HFD. (A), IL-6 (B) Leptin, (C) Resistin, (D)
VEGF-A, (E) TNF-α, (F) MCP-1, (G) PAI-1, and (H) Insulin. Results are presented as mean ± SEM (n = 6–9). Two-way ANOVA with Fisher’s LSD post hoc correction
was employed and p < 0.05 was considered as statistically significant. *p < 0.05.
levels were significantly higher in vehicle-H compared to vehicle-
L mice (p < 0.05, Figure 6B) and Dox-H compared to Dox-L
mice (p < 0.05, Figure 6B), respectively. Mice in the Dox-H
group showed significantly higher resistin (p < 0.05, Figure 6C)
and decreased VEGF-A levels (p< 0.05, Figure 6D) compared to
Dox-L mice. No significant differences were reported for TNF-α
(Figure 6E), MCP-1 (Figure 6F), PAI-1 (Figure 6G), and insulin
(Figure 6H) between any of the respective experimental groups.
Interleukin-10 and IL-1β were undetectable within all samples of
all the experimental groups.
Pearson’s correlation analysis revealed some positive
correlations between leptin and mammary adipose tissue
weight (Supplementary Figure 1). Significant strong positive
correlations were only observed for the doxorubicin treatment
groups (Dox-L, r = 0.78, p < 0.01, and Dox-H, r = 0.92, p =
0.001; Supplementary Figures 1C,D).
Lastly, Dox-H mice showed significantly higher protein
expression of nuclear factor kappa B (NFκB-p65) compared
to both Vehicle-H (p < 0.01) and Dox-L (p < 0.05) mice,
respectively (Figure 7A).
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FIGURE 7 | Western blot analysis of lipid metabolism marker protein expression in mammary adipose tissue of vehicle control and doxorubicin treatment groups on
LFD and HFD; (A) NFκB-p65, (B) FAS, (C) SCD-1, (D) HSL, (E) ATGL, and (F) FABP4. Results are presented as mean ± SEM (n = 6–8). Two-way ANOVA with
Fisher’s LSD post hoc correction was employed and p < 0.05 was considered as statistically significant. *p < 0.05, **p < 0.01.
Diet-Induced Obesity and Doxorubicin
Treatment Suppressed De novo
Lipogenesis and Lipolysis in Mammary
Adipose Tissue
Fatty acid synthase (FAS) and sterol CoA-desaturase-1 (SCD-
1) were found to be significantly decreased in the vehicle-H
mice, compared to vehicle-L mice (FAS, p < 0.01 and SCD-1,
p < 0.01 Figures 7B,C) and Dox-H mice compared to Dox-
L mice (FAS, p < 0.01, and SCD-1, p < 0.01 Figures 7B,C),
respectively. Moreover, hormone-sensitive lipase (HSL) was
significantly decreased in Dox-H compared to both vehicle-H
(p < 0.05, Figure 7D) and Dox-L mice (p < 0.05, Figure 7D).
No significant differences were observed for adipose triglyceride
lipase (ATGL) (Figure 7E) and fatty acid binding protein 4
(FABP4) (Figure 7F), between any of the respective experimental
groups (p> 0.05).
Diet-Induced Obesity Increased De novo
Lipogenesis and Lipolysis in Breast
Tumors Treated With Doxorubicin
Dox-H mice showed a significant increase in the protein
expression of SCD-1 and ATGL compared to vehicle-H
(SCD-1, p < 0.05 and ATGL, p < 0.01) and Dox-L
mice (SCD-1, p < 0.05 and ATGL, p < 0.01), in tumor
tissue (Figures 8A,B). Pearson’s correlation analysis showed
a significantly strong negative correlation between mammary
adipose tissue HSL protein expression and plasma resistin
concentration in the Dox-H group (r = −0.73, p < 0.05;
Supplementary Figure 2D).
Mammary Adipose- and Tumor Tissue
Fatty Acid Composition
Fatty acids for both mammary adipose (total lipid) and tumor
tissue (TPL) are summarized in Supplementary Tables 3, 4,
and a select few FAs are presented in graphs. The predominant
FA classes in mammary adipose tissue were monounsaturated
FAs (MUFAs) ranging from 43 to 51%, followed by SFAs
(27–30%) and polyunsaturated FAs (PUFAs; 21–27%) in
the treatment groups (Supplementary Figure 3). In the
tumor tissue TPL fraction the predominant FA classes
were SFAs ranging from 40 to 43%, followed by PUFAs
(32–38%) and MUFAs (19–28%) in all the experimental
groups (Supplementary Figure 4).
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FIGURE 8 | Western blot analysis of lipid metabolism protein expression in tumor tissue of vehicle control and doxorubicin treatment groups on LFD and HFD; (A)
SCD-1 (n = 5) and (B) ATGL (n = 4). Results are presented as mean ± SEM. Two-way ANOVA with Fisher’s LSD post hoc correction was applied and p < 0.05 was
considered as statistically significant. *p < 0.05, **p < 0.01.
Diet-Induced Obesity and Doxorubicin
Differentially Altered Saturated Fatty Acids
in the Tumor Microenvironment
Total SFAs (Σ SFAs) present in the tumor phospholipid fraction
was significantly higher in vehicle-H compared to vehicle-L
mice (p < 0.0001) and higher in Dox-H compared to Dox-
L mice (p < 0.0001) (Figure 9A). In mammary adipose tissue,
myristic acid (MA, C14:0) was significantly lower in the vehicle-
H mice compared to vehicle-L (p < 0.0001) and lower in
vehicle-L compared to Dox-L mice (p < 0.001), respectively
(Figure 9B).Myristic acid was also significantly lower in theDox-
H mice compared to Dox-L mice in tumor tissue (p < 0.05;
Figure 9B). Stearic acid (SA, C18:0) was significantly higher in
vehicle-H mice compared to vehicle-L (p< 0.0001) in mammary
adipose tissue. In addition, SA was also found to be significantly
higher in the Dox-H mice compared to Dox-L mice (p <
0.0001; Figure 9C). The tumor tissue SA percentage was also
higher in vehicle-H compared to vehicle-L mice (p < 0.0001)
and higher in Dox-H compared to Dox-L mice (p < 0.0001),
respectively (Figure 9C).
Diet-Induced Obesity and Doxorubicin
Suppressed Monounsaturated Fatty Acids
in the Tumor and in Surrounding Mammary
Fat
A similar and significant trend was observed for various MUFAs
in both mammary adipose tissue and tumor phospholipid
FAs. The total MUFAs (Σ MUFAs) and palmitoleic acid
(PTA, C16:1n-7) were significantly lower in vehicle-H
compared to vehicle-L mice and significantly lower in
Dox-H compared to Dox-L mice, respectively (all p <
0.0001, Figures 10A,B). In tumor tissue, oleic acid (OA,
C18:1n-9) was significantly lower in vehicle-H vs. vehicle-
L and Dox-H vs. Dox-L mice, respectively (p < 0.0001,
Figure 10C).
Diet-Induced Obesity and Doxorubicin
Selectively Increased Polyunsaturated
Fatty Acids in the Tumor Microenvironment
The total n-6 PUFAs (Σ n-6 PUFAs), linoleic acid (LA, C18:2n-
6) and eicosadienoic acid (EDA, C20:2n-6), were significantly
higher in the mammary adipose tissue of vehicle-H compared to
vehicle-L mice (Σ PUFAs, p < 0.0001, LA, p < 0.0001, EDA, p
< 0.0001), and higher in Dox-H than Dox-L mice, respectively
(Σ n-6 PUFAs, p < 0.0001, LA, p < 0.0001, EDA, p < 0.0001;
Figure 11). Similar results were observed in the tumor tissue total
phospholipid FA fraction i.e., higherΣ n-6 PUFAs, LA, EDA and
adrenic acid (ADA, C22:4n-6) levels in vehicle-H compared to
vehicle-L mice (Σ n-6 PUFAs, p< 0.0001, LA, p< 0.0001, EDA,
p < 0.0001, and ADA, p < 0.0001) as well as higher percentages
of these FAs in Dox-H compared to Dox-L mice (Figure 11).
Haematoxylin and Eosin Stained Tumors
Necrotic regions were detected in the tumor sections from
the vehicle-L mice. Necrosis was identified by cells with pale
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FIGURE 9 | Saturated fatty acid composition; (A) Total SFA, (B) Myristic Acid, and (C) Stearic Acid of mammary adipose- and tumor tissue of mice fed a LFD or HFD
with either vehicle control or doxorubicin treatment. Results are presented as mean ± SEM (n = 5). Two-way ANOVA with Fisher’s LSD post hoc correction was
applied and p < 0.05 was considered as statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001.
pink cytoplasm and areas of karyorrhectic debris (Figure 12A).
Necrosis was also detected in the tumors from the HFD vehicle
treated mice. Viable tumor cells demonstrated hyperchromatic
nuclei with coarse chromatin (Figure 12B). Tumors from both
the LFD and HFD vehicle mice demonstrated hyper- and
hypocellular regions and central areas of necrosis. Tumor
sections from the Dox-L mice resembled those of the vehicle-L
treated mice. In addition, multinucleated tumor cells were also
noted (Figure 12C). Sections from Dox-H mice had a similar
appearance (Figure 12D).
DISCUSSION
Diet-Induced Obesity Significantly
Decreased Doxorubicin Treatment Efficacy
in Breast Tumors
Similar to previous findings (33–35) we successfully establish
weight gain in our animal model. Body weight of animals
in the HFD group was significantly higher than those in the
LFD group, before (Figure 2A) and after tumor induction
irrespective of treatment (Figure 3A), which was corroborated
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FIGURE 10 | Monounsaturated fatty acid composition; (A) Total MUFAs, (B) Palmitoleic Acid and (C) Oleic acid of mammary adipose- and tumor tissue of mice fed a
LFD or HFD diet with either vehicle control or doxorubicin treatment. Results are presented as mean ± SEM (n = 5). Two-way ANOVA with Fisher’s LSD post hoc
correction was applied and p < 0.05 was considered as statistically significant. ****p < 0.0001.
by mammary adipose tissue weight. As expected, the Dox-
H mice had significantly lower food consumption compared
to vehicle-H mice (Figure 3B), which can be as a result of a
well-known side-effect of doxorubicin treatment (36), however
while the loss of appetite was visible, this had no effect on
body weight. Furthermore, we reported a significantly higher
volume (Figure 5) and weight (Figure 4B) of tumors in the
vehicle-H mice and in the Dox-H mice. This is in agreement
with previous studies reporting that DIO promoted tumor
growth. For example, Lautenbach et al. (37), observed that
female obese Sprague Dawley rats (HFD, 60% energy from fat
for 8 weeks) were more susceptible to tumor induction by
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FIGURE 11 | Polyunsaturated fatty acid composition; (A) Total n-6 PUFAs, (B) Linoleic Acid, (C) Eicosadienoic Acid, and (D) Adrenic Acid of mammary
adipose-and-tumor tissue of mice fed a LFD or HFD with either vehicle control or doxorubicin treatment. Results are presented as mean ± SEM (n = 5). Two-way
ANOVA with Fisher’s LSD post hoc correction was applied and p < 0.05 was considered as statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001 and
****p < 0.0001.
dimethylbenzathracene and also showed increased tumor growth
compared to controls. This was corroborated by Khalid et al.
(38), who found that a HFD (45% energy from fat) significantly
increased body weight and fat mass compared to mice on a
LFD (10% energy from fat) in a MMTV-HER2/Neu transgenic
breast cancer model, and that obesity promoted tumor growth,
reflected by an increase in tumor size. Additionally, Cowen et al.
(39) reported a higher body weight in female MMTV-PyMT
mice on a HFD (35.7% energy from fat) compared to mice on
a LFD (10% energy from fat), even after adjusting for tumor
weight and tumor volume. Others reported that DIO promotes
tumor growth, progression, and metastasis in animal models
(40, 41), specifically in breast cancer (16, 17, 33). In addition,
poor treatment outcomes are also reported in overweight and
obese breast cancer patients evident by larger tumor sizes and
poor clinical outcomes (7, 18, 42, 43) especially those treated with
doxorubicin (42, 44). It was also reported that DIO decreased
the efficacy of breast cancer treatment protocols in pre-clinical
animal models (33, 45).
Inflammatory Markers: Diet-Induced
Obesity Induces Systemic and Mammary
Fat Inflammation
Leptin was significantly increased in both the vehicle-H
and Dox-H groups compared to the respective control
LFD groups (Figure 6C). Leptin concentrations also
correlated positively with mammary adipose tissue weight
(Supplementary Figure 1). These results indirectly implicate
mammary adipose tissue, specifically adipocytes in the tumor
microenvironment as a source of leptin secretion in obese
mice, which also showed greater mammary adipose weight
(Figure 4A). Since E0771 breast cancer cells have been
shown not to produce leptin, even when co-cultured with
adipocytes, it therefore does not significantly contribute
to increased leptin levels (34). The increased mammary
adipose tissue weight as a result of the HFD could possibly
be one of the primary sources of leptin in our study.
We also reported that the resistin concentrations were
significantly increased in Dox-H compared to Dox-L mice
(Figure 6D).
Obesity is well-known to increase various pro-inflammatory
adipokine concentrations in serum and plasma as well as
adipose tissue (34, 46), whereas mRNA expression levels showed
that adipocytes co-cultivated with breast cancer cells also had
significantly higher IL-6, IL-1β, and TNF-α levels (7). It has
previously been shown that these elevated circulating cytokines
(i.e., IL-6 and IL-8) exerted effects at distant sites (47, 48),
this favors the progression of breast cancer by upregulating the
secretion of pro-inflammatory adipokines as well as exacerbates
immune cell infiltration, which in turn promoted cancer
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FIGURE 12 | Representative images of H&E stained tumor sections of the experimental treatment groups (A) vehicle-LFD, (B) vehicle-HFD, (C) Dox-L, (D) Dox-H,
Magnification = 4 and 20 x. Scale = 500µm.
progression through cellular proliferation, angiogenesis and the
inhibition of apoptosis (38, 39, 49). Evidence also supports the
role of obesity-induced inflammation (IL-6, TNF-α, and leptin)
in Tamoxifen R© and anti-VEGF acquired breast cancer drug
resistance (33, 50).
Leptin and resistin are well-known adipokines linked to
breast cancer (51). Both are secreted primarily by adipose
tissue, increase with higher degrees of adiposity, and has
been implicated for their role in obesity, inflammation, and
breast tumorigenesis (51–53). Breast cancer patients are
characterized by high serum leptin concentrations as well
as increased leptin receptor expression especially in higher
pathological grade tumor tissues and patients who develop
resistance to anti-cancer treatments (54, 55). Both leptin and
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resistin exacerbates an inflammatory microenvironment by
favoring the secretion of other pro-inflammatory adipokines.
Additionally, leptin favors breast cancer progression by
inducing cellular proliferation by binding to its receptor
followed by downstream signaling through NFκB, STAT3,
ERK1/ERK2, and phosphoinositide-3-kinase (PI3K) pathways
(56, 57). Both elevated leptin and resistin concentrations
was associated with the promotion of cancer stem cell
survival and the promotion of invasion and migration
via epithelial to mesenchymal transition in breast cancer
cells (55, 56, 58), which contributes to the development of
treatment resistance.
High concentrations of leptin and resistin favor cancer
cell proliferation and have recently been reported to
be casual factors in acquired breast cancer treatment
resistance (59). A well-known mechanism of developing
breast cancer treatment resistance includes the evasion
of apoptotic pathways (60, 61). Adipocytes attenuated
Doxorubicin-induced apoptosis in cancer cells by increasing
the protein expression of anti-apoptotic marker blc-2 as
well as increasing the synthesis of resistin (59, 61). Resistin
has also been identified as a causal factor for acquiring
resistance to doxorubicin treatment in both MCF-7 and
MDA-MB-231 breast cancer cells through the induction of
autophagy (59).
Furthermore, we also determined the protein expression
levels of NFκB, an important transcription factor regulating
inflammation, in mammary adipose tissue to confirm local
inflammation, and observed significantly higher levels of NFκB-
p65 protein expression in Dox-H compared to both the Vehicle-
H and Dox-L mice (Figure 7A). Mammary adipose tissue in
the tumor microenvironment displays persistent inflammation
and harbors crown like structures, which are well-known
inflammatory foci (62). We therefore propose that mammary
adipose tissue displays local inflammation (as a result of DIO)
similar to what is observed in visceral adipose tissue of obese
individuals (52, 63) and as a result may play a significant
role in obesity-induced breast cancer treatment resistance. It
is speculated that treatment resistance may be the result of
inflammation found in the mammary adipose tissue as a result
of the HFD and doxorubicin treatment. This is confirmed by
the fact that doxorubicin treatment induces inflammation in
metabolic tissues (64).
We, therefore conclude that inflammation as a result
of adipokine dysfunction was observed in obese vehicle-
treated mice and to a greater extent in doxorubicin treated
mice. We propose that obesity drives both systemic and
local inflammation in mammary adipose tissue and thereby
induce downstream signaling pathways regulating cell growth,
inhibition of apoptosis, and invasion, to ultimately contribute
to the development of breast cancer treatment resistance.
Therefore, it is plausible that DIO plays a key role as a
causal factor in the underlying pathophysiology linked to
the decreased efficacy of Doxorubicin treatment, involving
systemic and local mammary fat inflammation as underlying
molecular mechanisms.
Diet-Induced Obesity Distinctly Alters Lipid
Metabolism in the Tumor
Microenvironment Leading to Changes in
Fatty Acid Composition in Mammary
Adipose- and Tumor Tissue
We found that tumor tissue Σ SFA was increased in both
vehicle-H and Dox-H (HFD) mice compared to LFD mice
(Figure 9A). Stearic acid (SA) was also found to be increased
in mammary adipose tissue and tumor tissue of Dox-H mice
compared to Dox-Lmice (Figure 9C). Furthermore, we observed
decreased percentages of various MUFAs (PTA, OA, and VA)
in both mammary adipose and tumor tissue of mice on the
HFD, and even more profound decreases in doxorubicin-treated
mice (Figure 10).
Clinical and experimental animal model evidence on tumor
and adjacent adipose tissue induced FA composition alterations
within the tumor microenvironment are lacking specifically
under obesogenic conditions. Our results are in agreement with
Maillard et al. (65), who showed that the most abundant FAs
present in breast cancer tumors were OA, PA, SA, as well as
LA, compared to controls. de Bree et al. (66), reported that
breast cancer cases showed significantly higherΣ MUFA content
in tumor tissue as well as lower Σ PUFAs and n-6 PUFAs
content in breast adipose tissue, when compared to benign
cases. Mohammadzadeh et al. (67), confirmed increased OA,
arachidonic acid (AA) and MUFA:SFA ratio in breast tumors,
compared to adjacent tissue.
Due to the abundance and close proximity of mammary
adipose tissue (source of FAs) to breast cancer tumors, breast
tumors rely on lipid metabolism to favor survival by increasing
the expression of various proteins regulating lipid metabolism
(68, 69). This is evident by an upregulation of various enzymes
catalyzing de novo FA synthesis in breast cancer cells i.e., Acetyl-
CoA carboxylase (ACC), FAS and SCD-1 (13, 70, 71). Supporting
evidence includes increased exogenous lipid utilization, where
breast cancer cells induce adipocytes to release FFA via activation
of lipolysis (increased expression of ATGL and HSL) and
inhibition of adipogenesis (through decreased expression of
peroxisome proliferator-activated receptor-γ) (6, 8). Adipocyte-
derived FFAs favor the proliferative nature of breast tumor cells
in the tumor microenvironment (8), by serving as available
metabolic substrates for energy production via β-oxidation or
storage in the form of lipid droplets for later utilization. In
contrast, microscopically, regions with varying cellularity were
observed in tumor sections of both vehicle treated groups
irrespective of diet (Figures 12A,B). Hyper-cellular regions also
showed darker staining on low-power magnification, indicative
of increased cell proliferation. Sections of the Dox-Lmice showed
mostly hyper-cellular regions (Figure 12C), whereas the tumor
sections of the Dox-H mice were less cellular (Figure 12D). This
may indicate a decrease in cellular proliferation in response to
Doxorubicin treatment among the HFD fed mice. Therefore,
it may also be plausible that adipocyte-derived FFAs can
induce survival via other mechanisms of action other that
proliferation. A recent report showed that lipid accumulation
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(adipocyte derived FFA) leads to uncoupled FA oxidation, which
favored invasion due to epithelial-mesenchymal-transition, but
not proliferation (72).
Additionally, adipocyte-derived FFAs can also be
incorporated into phospholipids and esterified with cholesterol
to produce cholesteryl esters in cell membranes (73, 74) to
induce lipid-saturated membranes. This is further supported by
the increased amount and size of lipid droplets found in breast
cancer tumors, specifically more aggressive phenotypes (6, 73).
Therefore, it may also be plausible that the increased tumor
volume in the HFD fed groups maybe be as a result of membrane
lipid saturation and lipid droplet deposition within tumor tissue.
In fact, tumors enriched with lipid droplets (TAGs and sterol
esters) were found to be more resistant toward chemotherapeutic
agents (75).
Fatty acids are essential components of cell membrane
organization (phosphoglycerides) and fluidity (degree of carbon
chain unsaturation), and it is known that the type of
FA (i.e., increased saturated FAs characteristic of obesity)
derived from the diet, affects phospholipid FA composition
(densely-packed membranes) and physical-chemical properties
(decreased transmembrane permeability) in cancer cells. This
metabolic behavior protects breast cancer cells from oxidative
damage induced by chemotherapeutic drugs by decreasing
lipid peroxidation, ultimately leading to acquired treatment
resistance (11, 76).
The decreased SFA and MUFA profiles observed in mammary
adipose tissue could possibly be as a result of alterations in
the expression of enzymes regulating lipogenesis, since PA can
be elongated into SA, as well as desaturated (catalyzed by
SCD-1) to produce PTA (77). We found a decrease in FAS
(Figure 7B) and SCD-1 protein expression (Figure 7C) in HFD
mice (both vehicle- and doxorubicin-treated) within mammary
adipose tissue, which translate to a decrease in lipogenic activity
in mammary adipose tissue of the HFD (obese) animals.
This was further supported by decreased estimated activity
of SCD1-16 and SCD1-18 (desaturation indexes) observed in
HFD compared to LFD animals in mammary adipose tissue
FA composition, specifically in the doxorubicin-treated mice
(Supplementary Table 3). Our findings can be explained by the
high dietary carbohydrate content of the LFD i.e., 70% energy
from carbohydrates, which might partially explain why SCD-1
and FAS expression was higher in the LFD mice, irrespective of
treatments, as dietary carbohydrates are substrates for de novo
FA synthesis. Our results are in agreement with Liu et al. (78),
who showed that rats fed a HFD (60% energy from fat) compared
to a control diet (10% energy from fat), showed decreased SCD-
1 estimated activity derived from FA composition in adipose
tissue TAG and serum FFA fractions. Additionally, it may also
be possible that a HFD suppresses SCD-1 expression to prevent
adipose tissue storage of FAs in order to promote β-oxidation.
This could have implications for tumor-cell survival since an
increase in β-oxidation is linked to increased energy production
which breast cancer cells utilize for survival, and/or to evade
the toxic effects of cancer treatments. This provides a plausible
explanation for the HFD-induced decreased lipogenic/lipolytic
activity in mammary adipose tissue to increase the FFA “pool”
by preventing fat storage (TAGs), which is also exacerbated
by doxorubicin treatment—all of which may contribute to the
attenuation of breast cancer treatment efficacy. We propose that
the excess lipid “availability” in mammary adipose tissue of obese
patients could explain the resistance to treatment protocols found
in breast cancer patients, especially since dysfunctional adipose
tissue (obesity) is implicated in breast cancer progression (79)
and because “obese” adipocytes provide higher concentrations of
FFAs to breast cancer cells to sustain survival and migration (8).
However, the increased SCD-1 expression observed in Dox-
H compared to Dox-L mice in tumor tissue (Figure 8A) does
not account for the decreased MUFAs found in the tumor
tissue of Dox-H mice (Figure 10). Firstly, the decreased MUFA
profile may be as a result of increased lipolysis of lipid
droplets within the tumor itself, as evident by the increased
expression of ATGL in the tumor tissue of the HFD mice
(Figure 8B). Additionally, it could also be the result of breast
tumor cells utilizing these MUFAs to decrease treatment efficacy,
by increasing the release of MUFAs from the cell membrane.
This is supported, by the decreased MUFAs observed within
the tumor tissue FFA fraction, including PTA, VA, gondoic
acid (GA), and nervonic acid (NA), in the Dox-H compared
to Dox-L groups (Supplementary Table 5). Lastly, the decreased
MUFAs found in tumor tissue TPL and FFA fractions can also
be explained by the preferential release and low re-uptake of
MUFAs in specific tissues, as well as the selective preference of
SFAs compared to MUFAs, or the selective decrease of MUFAs-
containing phosphatidylethanolamines and phosphatidylcholine
lipids present in tumors under obesogenic conditions. Taken
together, the HFD (obesity) induced both de novo FA synthesis
and lipolysis in the tumor, which was exacerbated by the
doxorubicin treatment itself and might therefore confer to
the attenuation of breast cancer treatment efficacy under
obesogenic conditions.
Furthermore, a dysregulation of cytokines (i.e., increased IL-
6, TNF-α, and IL-1β) and adipokines, such as increased leptin
and decreased adiponectin (80–83) has been shown to induces
transcriptional changes. For example leptin has been shown to
inhibit lipogenesis by altering the expression of transcription
factors involved in lipid metabolism (7, 45). The outcome is
altered adipocyte endocrine functionality which can favor tumor
cells to produce more adipokines (83).
We observed increased leptin and resistin levels in Dox-H
compared to Dox-L mice (Figures 6C,D). Previously, elevated
TNF-α levels have been shown to inhibit adipocyte lipolysis
(84) and high leptin levels have been shown to decrease
adipose tissue SCD-1 expression (85). We believe that obesity-
induced inflammation (increased resistin levels) may lead to
lipolysis inhibition (decreased HSL in Dox-H vs. Dox-L mice) in
mammary adipose tissue (Figure 7D). In agreement, we found
a significant negative correlation between resistin concentration
and HSL protein expression in mammary adipose tissue in
the Dox-H mice (Supplementary Figure 2), which is supported
by previous studies showing that high SFA levels induce the
secretion of pro-inflammatory mediators via the NFκB signaling
pathway, via the TLR-4 on macrophages (86, 87), which might in
turn inhibit lipolysis (decreased HSL). This is also in agreement
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with our results, since we found higher levels of NFκB protein
expression in mammary adipose tissue of Dox-H compared Dox-
L mice (Figure 7); all of which further promotes inflammation
in the mammary adipose tissue environment, favoring breast
cancer cell survival and thereby decreasing treatment efficacy in
a paracrine manner.
Furthermore, both mammary adipose tissue and tumor tissue
showed significant increases in various n-6 PUFAs (LA, EDA,
and ADA) in vehicle-H and Dox-H mice compared to LFD mice
(Figure 11). Linoleic acid and ALA are essential FAs derived
from the diet (88). These FAs are desaturated (FA desaturases)
and elongated (Elovl2 and Elovl5) to form their respective long-
chain polyunsaturated products such as AA and eicosapentaenoic
acid (EPA) (88). Both the low-fat and high-fat experimental diets
in our study contained soybean oil, which is rich in both LA
and ALA. Therefore, the increase in PUFAs found in both the
mammary adipose tissue and the tumor tissue of the HFD mice
may be reflective of the higher total fat content (and therefore
PUFA content) of the HFD (60% energy from fat).
The proportions of FAs within the two respective diets differed
significantly. Linoleic acid and AA accounted for the elevation of
n-6 PUFAs in both mammary and tumor tissue of HFD-fed mice,
suggesting an increased inflammatory profile, specifically in the
obese doxorubicin-treated mice. The pro-inflammatory effects
of n-6-PUFA is as a result of lipid-derived bioactive eicosanoid
mediators, such as prostaglandins and leukotrienes (14, 89).
These bioactive lipids are implicated in breast cancer progression
by favoring angiogenesis, cellular proliferation and survival, cell
migration, metastasis, as well as exacerbating inflammation (15,
90), in the breast tumor microenvironment possibly promoting
acquired cancer resistance to anti-cancer treatment agents.
More importantly, doxorubicin treatment causes adipose
tissue and/or adipocyte dysfunction, by altering lipogenesis
(decreased FAS) and lipolysis (increased HSL) (20–22, 64,
91), which participate toward the disruption of adipose tissue
homeostasis. The consequence here is an increase in FFA
release that disrupts lipid storage (22). Doxorubicin-induced
FFA release may further exacerbate the bioavailability of
FFA, which cancer cells can utilize favorably for its survival
and proliferation demands, and thereby indirectly promote
breast cancer treatment resistance. Recently, Ebadi et al.
(92), showed that chemotherapy treatment (5-fluorouracil and
Irinotecan) in a colorectal cancer model diminished peri-
uterine adipose tissues’ function to store lipids by significantly
downregulating the expression of ACC, FAS, and HSL, as
well as markers of β-oxidation (i.e., CPT-2), compared to
treatment-naïve rats. Additionally, they also showed that
SFAs (PA) and MUFAs (PTA) were significantly decreased in
chemotherapy-treated groups. However, the authors explained
that it is still unknown whether the suppression of adipose
tissue lipid storage capacity induced by chemotherapy is a
result of decreased HSL expression, or due to mitochondrial
dysfunction induced by the chemotherapy (92). Mehdizadeh
et al. (93) showed that doxorubicin and 5-fluorouracil have
FIGURE 13 | Summary of findings. DIO selectively supresses de novo FA synthesis and lipolysis in mammary adipose tissue, but increased lipogenesis and lipolysis in
tumor tissue. Exogenous dietary lipids can alter the energy metabolism of triple-negative breast cancer tumors in this current in vivo model. Alterations in FAs
composition in both mammary adipose and tumor tissue could be a mechanism by which FAs composition can be altered in response to DIO within the tumor
microenvironment and thereby contributing to the decreased efficacy of breast cancer treatment agent within our current model.
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the ability to induce cancer cell invasion and metastasis by
increasing lipid accumulation and membrane fluidity, by altering
lipid metabolism. For example, doxorubicin and 5-fluorouracil
treatment significantly increased the number of lipid droplets
within HepG2 cancer cells. They also reported a significant
increase in SFAs (PA) and PUFAs and a significant decrease
in MUFAs (OA and PTA) following chemotherapy treatments
in the phospholipid fractions of the membranes of cancer
cells (93).
To summarize, evidence on FA profiles within the tumor
microenvironment has not yet been explored in an obese breast
cancer animal model to specifically illustrate its role in breast
cancer treatment efficacy. We provide evidence that diet-induced
obesity altered the FA profile of both the tumor tissue and its
adjacent surrounding mammary adipose tissue. The expression
of lipid metabolism enzymes in this study were also differentially
altered by diet-induced obesity and it is very likely that the altered
FA composition observed in both mammary adipose tissue and
tumor tissue are as a result of alterations in lipogenesis and/or
lipolysis, which may be a causal factor in decreasing the efficacy
of doxorubicin a well-known breast cancer treatment agent. We
acknowledge that the fat content used in the HFD (60% energy
from fat) of the in vivo model is high in comparison to human
consumption. However, Ervin et al. (94) suggested that although
the total fat content is high, the proportion of specific FA classes
(SFAs, MUFAs, and PUFAs) consumed in humans is similar to
the HFD we used (94).
CONCLUSION
Diet-induced obesity significantly decreased the treatment
efficacy of doxorubicin on triple-negative breast cancer tumors.
Suppression of both de novo FA synthesis and lipolysis in
mammary adipose tissue lead to the inhibition of FA storage
(decreased MUFAs and increased PUFAs), exacerbating
local inflammation in mammary adipose tissue which can
enhance breast cancer cell survival in a paracrine manner, as
illustrated in Figure 13. De novo FA synthesis and lipolysis
were increased in breast tumor tissue. The incorporation of
dietary FAs into phospholipid membranes of breast tumor
cells suggests that exogenous dietary lipids can alter the energy
metabolism of E0771 breast cancer cells. These selective
alterations in lipid metabolism markers and FA composition
in both mammary adipose and tumor tissue could be a
novel mechanism by which FA composition can be altered
in response to DIO within the tumor microenvironment and
thereby contributing to the development of breast cancer
treatment resistance. When doxorubicin is administered
as a treatment in an obesogenic context, the treatment
efficacy of this breast cancer treatment agent is decreased
by conferring to a more lipid saturated cell membrane,
known to protect cancer cells from the cytotoxic effects of
chemotherapeutic agents.
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